India's Non-Small-Cell Lung Cancer Drug Market Will Almost Doub... ( Western Branded Drug Sales Will Comma...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

India's Non-Small-Cell Lung Cancer Drug Market Will Almost Double by 2013

Date:5/13/2009

Western Branded Drug Sales Will Command 54 percent of the Market by 2013, According to a New Report from Decision Resources

WALTHAM, Mass., May 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in India will almost double by 2013, growing from $27.7 million in 2008 to $52.1 million in 2013. This growth will be fueled by an increased uptake of antimetabolites and targeted therapies. In fact, the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitor drug classes will dominate the market throughout the forecast period with a combined market share of 55 percent by 2013.

The new Emerging Markets report entitled Non-Small-Cell Lung Cancer in India also finds that Western-branded drug sales in India's non-small-cell lung cancer market will command 54 percent by 2013. Even though Western-branded small-molecule agents are facing fierce competition from domestic products, including gefitinib (in the U.S. known as AstraZeneca's Iressa) and erlotinib (in the U.S. known as Genentech's Tarceva), future opportunities for Western companies will depend heavily on their pricing strategies and their patent protection in India. Moreover, monoclonal antibodies will surge and won't be copied successfully during the report's 2008 - 2013 forecast period.

"Opportunity for Western companies penetrating or wanting to penetrate India's non-small-cell lung cancer (NSCLC) drug market lies in forming alliances with Indian companies in order to negotiate the complex regulatory process of getting new NSCLC therapies to market," stated Manashi Sherawat, Ph.D., analyst at Decision Resources. "Opportunity also lies in raising awareness of this form of cancer in
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
2. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
3. Survival differences by race most apparent in advanced stages of breast cancer
4. MRI finds breast cancer before it becomes dangerous
5. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
6. Pathway links inflammation, angiogenesis and breast cancer
7. Radiologists encouraged to look beyond cancer for clinically unseen diseases
8. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
9. Immune deficiency linked to a type of eye cancer
10. Drop in breast cancer incidence linked to hormone use, not mammograms
11. Breast cancer prevention practices vary across Canada

Post Your Comments:

Breaking Medicine News(10 mins):Health News:Early Treatment of Hearing, Vision Helps in Schizophrenia 2 Health News:Study shows how gene action may lead to diabetes prevention, cure 2 Health News:The Visiting Nurse Association of Greater Philadelphia Expands Service to Bucks County 2 Health News:Autism Research at the Children's Hospital of Philadelphia Is Among Time Magazine's Top 10 Medical Breakthroughs 2 Health News:IOM report on national vaccine plan 2 Health News:IOM report on national vaccine plan 3

[0] Early Treatment of Hearing, Vision Helps in Schizophrenia [0] Study shows how gene action may lead to diabetes prevention, cure [0] The Visiting Nurse Association of Greater Philadelphia Expands Service to Bucks County [0] Autism Research at the Children's Hospital of Philadelphia Is Among Time Magazine's Top 10 Medical Breakthroughs [0] IOM report on national vaccine plan

Gene variant predicts medication response in patients with alcohol dependence Assurant President and Chief Executive Officer Robert B. Pollock to Present at Merrill Lynch Insurance Investor Conference on February 12 New Natural Energy Bar Hits the Road with Dieters & Athletes Alike Lower-income neighborhoods associated with higher obesity rates American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter Parsons Announces Start of Wi-Fi Service on Fauntleroy/Vashon/Southworth Ferry Run

Breaking Medicine Technology:Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5 IEEE USA President endorses national innovation strategy 10050 1 Diamonds may be the ultimate MRI probe say Quantum physicists 10047 1 Diamonds may be the ultimate MRI probe say Quantum physicists 10047 2 The Lupus Foundation of America Inc Asks Supporters to Band Together for Lupus 28SM 29 58093 1 The Lupus Foundation of America Inc Asks Supporters to Band Together for Lupus 28SM 29 58093 2

[0] Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg [0] Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round [0] Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy

Other Medicine Technology:Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2 Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3 Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6

Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference

Medicine Products:

Girard Tying Forceps - Curved Trouan Tying Forceps Miltex Hartman Mosquito Forceps Hartman Hemostatic Mosquito Curved forceps

India's Non-Small-Cell Lung Cancer Drug Market Will Almost Doub...( Western Branded Drug Sales Will Comma...),Health